GlassScriptPhysician profile
Mehul Shah
NPI 1326129214
$5,080.58
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,233 · 2020: $1,076 · 2021: $1,094 · 2022: $769 · 2023: $780 · 2024: $128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $908.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $908.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,497.47 | 2019-2024 | Farxiga, Breztri |
| Glaxosmithkline, LLC. | $1,055.97 | 2019-2023 | Trelegy Ellipta, Shingrix |
| Janssen Pharmaceuticals, INC | $700.83 | 2019-2023 | Xarelto |
| Lilly USA, LLC | $518.60 | 2019-2023 | Mounjaro, Trulicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $307.85 | 2019-2021 | |
| Novo Nordisk INC | $159.80 | 2019-2021 | |
| Ucb, INC. | $135.05 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $114.40 | 2021-2023 | |
| Amarin Pharma, INC. | $110.40 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $75.64 | 2021-2023 | |
| Pfizer INC. | $71.73 | 2019-2023 | |
| Amgen INC. | $55.57 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $52.80 | 2021 | |
| Indivior INC. | $46.04 | 2019 | |
| Xeris Pharmaceuticals, INC. | $41.84 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $23.60 | 2021 | |
| Portola Pharmaceuticals, LLC | $23.33 | 2019 | |
| Allergan, INC. | $20.52 | 2019 | |
| Ge Healthcare | $19.28 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $18.95 | 2022 | |
| Astellas Pharma US INC | $15.52 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $15.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mehul Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.